Recent advances in chemotherapy for advanced prostate cancer

被引：6

作者：

Olson K.B. ^{[1
]}

Pienta K.J. ^{[1
]}

机构：

[1] Urologic Oncology, University of Michigan Medical Center, 1500 East Medical Center Drive, 7303 CCGC, Ann Arbor, 48109, MI

来源：

Current Urology Reports | 2000年 / 1卷 / 1期

关键词：

Docetaxel; Estramustine; Prostate Cancer; Taxotere; Vinorelbine;

D O I：

10.1007/s11934-000-0035-z

中图分类号：

学科分类号：

摘要：

Recently, several important studies have validated prostatespecific antigen (PSA) as a reliable measure of response to chemotherapeutic treatment in advanced hormonerefractory prostate cancer. Furthermore, although chemotherapy in this setting has always been considered palliative, several analyses of recent clinical trials have demonstrated a significant association between declines in PSA values of 50% or more and prolonged survival. Mitoxantrone, in combination with prednisone, has been shown to provide significant palliation and improved quality of life. The use of combinations of chemotheraputic agents also seems to provide significantly superior objective and subjective responses compared with single-agent regimens. In particular, estramustine has been shown to synergize many of the agents used in prostate cancer treatment and has been demonstrated to provide significant palliation and decline in PSA levels in combination with vinblastine, vinorelbine, etoposide, paclitaxel, and docetaxel. The results of several important trials of the taxanes both as single agents and in combination with estramustine have been completed in the past year and have demonstrated that these agents are very effective in the treatment of hormone-refractory prostate cancer. © 2000, Current Science Inc.

引用

页码：48 / 56

页数：8

共 56 条

[41]

Dimopoulos M.A., Panopoulos C., Bamia C., Et al., Oral estramustine and oral etoposide for hormone-refractory prostate cancer, Urology, 50, pp. 754-758, (1997)

[42]

Smith D.C., Esper P., Strawderman M., Et al., Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer, J Clin Oncol, 17, pp. 1664-1671, (1999)

[43]

Earhart R., Docetaxel (Taxotere): Preclinical and general clinical information, Semin Oncol, 26, pp. 8-13, (1999)

[44]

Friedland D., Cohen J., Miller R., Et al., A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of BCL02, Semin Oncol, 26, pp. 19-23, (1999)

[45]

Picus J., Schultz M., Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results, Semin Oncol, 26, pp. 14-18, (1999)

[46]

Kreis W., Budman W., Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer, Semin Oncol, 26, pp. 34-38, (1999)

[47]

Petrylak D.P., Macarthur R.B., O'Connor J., Et al., Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer, J Clin Oncol, 17, pp. 958-967, (1999)

[48]

Petrylak D.P., Macarthur R.B., O'Connor J., Et al., Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer, Semin Oncol, 26, pp. 28-33, (1999)

[49]

Sinibaldi V.J., Carducci M., Laufer M., Eisenberger M., Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer, Semin Oncol, 26, pp. 45-48, (1999)

[50]

Savarese D., Taplin M.E., Halaabi S., Et al., A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B trial 9780, Semin Oncol, 26, pp. 39-44, (1999)

← 1 2 3 4 5 6 →